Cenerimod Shows Promise in Treating Systemic Lupus Erythematosus: Phase 2b CARE Study Results
核心洞察
The Phase 2b CARE study demonstrated that cenerimod, a selective S1P1 receptor (搜索) modulator, led to clinically meaningful improvements in adults with moderate-to-severe SLE (搜索).
Patients treated with cenerimod 4 mg showed significant and lasting improvements in SLE (搜索) disease activity compared to placebo, alongside stable background therapy.
Biomarker data from the CARE study further elucidated cenerimod's immunomodulatory effects on lymphocytes, inflammation, and antigen transport in SLE (搜索) pathogenesis.
Viatris Inc. (NASDAQ: VTRS) has announced the publication of Phase 2b CARE study results, revealing the efficacy and safety of cenerimod in treating adults with moderate-to-severe systemic lupus erythematosus (搜索) (SLE (搜索)). The study's findings, published in Lancet Rheumatology, indicate that cenerimod at a 4 mg dosage led to clinically meaningful and sustained improvements in SLE disease activity compared to a placebo, when used in conjunction with stable background SLE therapy.
CARE Study Design and Results
The CARE study was a Phase 2b, multicenter, randomized, double-blind, placebo-controlled trial involving adults aged 18-75 years with moderate-to-severe SLE (搜索). Of the 810 patients screened, 427 were randomly assigned to receive either once-daily oral cenerimod (0.5 mg, 1 mg, 2 mg, or 4 mg) or a placebo, in addition to their stable background SLE therapy, and were monitored for 12 months. The primary endpoint was the change from baseline to month 6 in the modified SLE Disease Activity Index 2K (mSLEDAI-2K) score.
Results from the CARE study showed that at month 6, the 4 mg cenerimod group exhibited the maximum response, with a least squares mean change from baseline in mSLEDAI-2K score of -4.04 (95% CI -4.79 to -3.28; difference vs placebo -1.19 [-2.25 to -0.12]; p=0.029). Furthermore, a subgroup analysis revealed that patients with a high IFN-1 gene expression signature treated with cenerimod 4 mg showed a greater reduction in mSLEDAI-2K at month 6 (-2.78) compared to placebo. This subgroup also demonstrated a 24% higher SLE (搜索) Responder Index (SRI-4) response rate compared to placebo.
Cenerimod's Mechanism of Action
Additional results from the analysis of SLE (搜索)-related biomarker data from the CARE study, published in the Annals of the Rheumatic Diseases, further elucidated cenerimod's mechanism of action. The data indicated that cenerimod 4 mg significantly reduced IFN-γ-associated proteins, as well as IFN-1 protein and gene expression signature biomarkers, after 6 months of treatment compared to placebo. This effect was more pronounced in patients with high IFN-1 expression, supporting the stronger clinical response observed in this population.
Philippe Martin, Viatris Chief R&D Officer, stated, "The biomarker data highlights the multifaceted immunomodulatory properties of cenerimod targeting key aspects of SLE (搜索) pathogenesis."
Safety and Tolerability
Over the 12-month treatment and follow-up period, most adverse events (AEs) were mild to moderate, and no serious adverse events (SAEs) were related to cenerimod. The drug was generally well-tolerated at all doses evaluated.
Ongoing Phase 3 OPUS Program
The data from the CARE study informed the design and dose selection for the ongoing Phase 3 OPUS program (OPUS-1 NCT05648500, OPUS-2 NCT05672576, OPUS-OLE NCT06475742), which aims to evaluate the efficacy, safety, and tolerability of cenerimod in adult patients with moderate-to-severe SLE (搜索) on top of background therapy. The primary endpoint of the OPUS program is the response on SRI-4 at month 12 compared to baseline.
About Cenerimod and SLE
Cenerimod is an investigational, highly selective sphingosine-1-phosphate 1 (S1P1) receptor modulator administered orally once daily. It targets SLE (搜索) pathogenesis through immunomodulatory effects on lymphocytes, inflammation, and antigen transport. Systemic lupus erythematosus (搜索) (SLE) is a complex autoimmune disease characterized by aberrant immune system activity, including lymphocyte activation, autoantibody production, and activation of inflammatory cytokine pathways.